QuidelOrtho logo

QuidelOrthoNASDAQ: QDEL

Profile

Sector:

Healthcare

Country:

United States

IPO:

01 February 1991

Next earnings report:

13 February 2025

Last dividends:

N/A

Next dividends:

N/A
$2.58 B
-64%vs. 3y high
84%vs. sector
-vs. 3y high
-vs. sector
-81%vs. 3y high
35%vs. sector
-76%vs. 3y high
22%vs. sector

Price

pre-market | 67 min ago
$38.43+$0.54(+1.43%)

Dividend

No data over the past 3 years
$727.10 M$702.89 M
$727.10 M-$19.90 M

Analysts recommendations

Institutional Ownership

QDEL Latest News

QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group
businesswire.com19 November 2024 Sentiment: NEUTRAL

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the launch of an underwritten secondary offering (the “Offering”) by Carlyle Partners VI Cayman Holdings, L.P. (the “Selling Stockholder”) of 8,260,183 shares of the Company's common stock (“Common Stock”). The Selling Stockholder will rec.

Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm
prnewswire.com13 November 2024 Sentiment: NEGATIVE

NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, QuidelOrtho insiders caused the company to misrepresent or fail to disclose that (a) QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (b) excess inventories of COVID-19 tests existed throughout the supply chain; (c) as a result, QuidelOrtho's distributors and pharmacy chain customers were poised to significantly reduce their COVID-19 test orders; (d) undisclosed problems created a heightened risk that the new test called the savanna respiratory viral panel-4 test would experience a delayed commercial launch in the United States; (e) as a result, the company lacked a reasonable basis for positive statements about QuidelOrtho's business, financials, and growth trajectory.

QuidelOrtho Stock Rises as Q3 Earnings & Revenues Beat Estimates
zacks.com08 November 2024 Sentiment: POSITIVE

QDEL's third-quarter results reflect growth in non-respiratory revenues along with a lowering of operating expenses year over year. However, the gross margin declines in the reported quarter.

QuidelOrtho (QDEL) Beats Q3 Earnings and Revenue Estimates
zacks.com07 November 2024 Sentiment: POSITIVE

QuidelOrtho (QDEL) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.90 per share a year ago.

Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm
globenewswire.com31 October 2024 Sentiment: NEGATIVE

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached their fiduciary duties to shareholders.

QuidelOrtho to Participate in Three Upcoming Investor Conferences
businesswire.com28 October 2024 Sentiment: POSITIVE

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend three upcoming investor conferences and participate in fireside chats at all three conferences. UBS Global Healthcare Conference On Tuesday, November 12, 2024, QuidelOrtho is scheduled to part.

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
zacks.com08 October 2024 Sentiment: POSITIVE

QDEL's strong product portfolio raises optimism about the stock.

Why QuidelOrtho Stock Blasted 10% Higher Today
fool.com05 September 2024 Sentiment: POSITIVE

An analyst became notably more bullish on the diagnostics company's prospects. He upgraded his recommendation from hold to buy.

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
zacks.com03 September 2024 Sentiment: POSITIVE

QDEL's strong product portfolio raises optimism about the stock.

QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod
zacks.com30 August 2024 Sentiment: POSITIVE

QDEL announces the FDA's clearance for its VITROS syphilis assay, which boosts the company's infectious disease testing portfolio.

What type of business is QuidelOrtho?

Quidel Corporation is a manufacturer of medical diagnostic supplies. The company produces a wide range of tests, reagents, devices, and other products for diagnosing viral and bacterial infections, autoimmune diseases, and detecting markers of inflammation. The company also produces bacterial cultures, conducts research in the field of diagnosing oncological diseases, diabetes, and so on. One of the popular solutions from Quidel is the Triage device for rapid detection of prohibited substances in patients' bodies. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.

What sector is QuidelOrtho in?

QuidelOrtho is in the Healthcare sector

What industry is QuidelOrtho in?

QuidelOrtho is in the Medical Devices industry

What country is QuidelOrtho from?

QuidelOrtho is headquartered in United States

When did QuidelOrtho go public?

QuidelOrtho initial public offering (IPO) was on 01 February 1991

What is QuidelOrtho website?

https://www.quidelortho.com

Is QuidelOrtho in the S&P 500?

No, QuidelOrtho is not included in the S&P 500 index

Is QuidelOrtho in the NASDAQ 100?

No, QuidelOrtho is not included in the NASDAQ 100 index

Is QuidelOrtho in the Dow Jones?

No, QuidelOrtho is not included in the Dow Jones index

When was QuidelOrtho the previous earnings report?

No data

When does QuidelOrtho earnings report?

The next expected earnings date for QuidelOrtho is 13 February 2025